Selective laser trabeculoplasty is safe and effective in patients previously treated with prostaglandin analogs: An evidence-based review

Ruiz-Lozano, Raúl E.; Alamillo-Velazquez, Jimena; Ortiz-Morales, Gustavo; Garza-Garza, Lucas A.; Quiroga-Garza, Manuel E.; Alvarez-Guzman, Carlos; Rodríguez-García, Alejandro

doi:10.1007/s10792-022-02460-w

Cited by 4 publications

(2 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, a multicenter trial funded by the US National Institutes of Health/National Eye Institute—the Clarifying the Optimal Application of SLT Therapy (COAST) trial—is currently investigating the role of annual low-energy SLT compared to standard-energy SLT performed as needed in keeping newly diagnosed OAG and OHTN patients off medications for as long as possible [ 149 ]. From an economic perspective, compared to topical medical therapy, SLT has been shown to be more cost-effective [ 69 , 130 , 150 – 152 ].…”

Section: Discussion: Beyond Medications: a Modern Interventional Glau...mentioning

confidence: 99%

Challenging the "Topical Medications-First” Approach to Glaucoma: A Treatment Paradigm in Evolution

Radcliffe,

Shah,

Samuelson

2023

Ophthalmol Ther

View full text Add to dashboard Cite

Topical glaucoma medications are effective and safe, but they have numerous well-documented limitations that diminish their long-term utility and sustainability. These limitations can include high rates of nonadherence (with associated glaucoma progression), concerning side effects, inconsistent circadian intraocular pressure (IOP) control, complex dosing regimens, difficulty with self-administration, costs, and decreased quality of life. Despite these limitations, topical medications traditionally have been first-line in the glaucoma treatment algorithm, as no other minimally invasive treatment alternatives existed. In recent years, however, novel interventional therapies—including sustained-release drug-delivery platforms, selective laser trabeculoplasty, and micro-invasive glaucoma surgery procedures—have made it possible to intervene earlier without relying on topical medications. As a result, the topical medication-first treatment approach is being reevaluated in an overall shift toward earlier more proactive interventions.

show abstract

Section: Discussion: Beyond Medications: a Modern Interventional Glau...mentioning

confidence: 99%

Challenging the "Topical Medications-First” Approach to Glaucoma: A Treatment Paradigm in Evolution

Radcliffe,

Shah,

Samuelson

2023

Ophthalmol Ther

View full text Add to dashboard Cite

show abstract

“…10 Studies have shown that IOP lowering is similar with SLT and topical medication, 11 and there are data supporting the use of SLT as first-line therapy in OAG and OHT. [12][13][14] Nonetheless, SLT is mainly used as an adjunctive treatment in patients requiring additional IOP-lowering beyond that achieved with eye drops. 12 It is commonly understood that it may take 1 to 2 months for the full effect of SLT on IOP to be achieved, and the IOP-lowering effect subsides over time, but the procedure effectively lowers IOP when repeated, 15 and a second SLT treatment can be as successful as the initial procedure.…”

Section: Introductionmentioning

confidence: 99%

Phase 3, Randomized Study Comparing Intracameral Bimatoprost Implant 15 μg and Selective Laser Trabeculectomy in Patients with Open-Angle Glaucoma or Ocular Hypertension

Christie,

Basha,

et al. 2023

OPTH

View full text Add to dashboard Cite

Purpose We evaluate the safety and intraocular pressure (IOP)-lowering effect of 15-µg bimatoprost implant (higher dose than the currently approved product) compared with selective laser trabeculoplasty (SLT) in patients with open-angle glaucoma or ocular hypertension. Methods Randomized, phase 3, 12-month, multicenter, paired-eye, patient- and efficacy evaluator–masked noninferiority study. Patients with inadequate IOP control were randomized to receive 360° SLT (day 1) or up to 3 administrations of 15-µg bimatoprost implant (day 4, weeks 16 and 32) in the primary eye and the alternative treatment in the contralateral eye. The primary endpoint was IOP change from baseline at weeks 4, 12, and 24. Results At weeks 4, 12, and 24, mean IOP change from baseline ranged from −7.01 to −6.65 mm Hg in implant-treated eyes (N=138) and −6.45 to −6.26 mm Hg in SLT-treated eyes (N=138). Differences in IOP change from baseline ranged from −0.70 to −0.25 mm Hg favoring implant; the upper limit of the 95% confidence interval of the difference (implant minus SLT) was <1.0 mm Hg at all 3 visits. The probability of requiring no additional (rescue) IOP-lowering treatment in implant-treated versus SLT-treated eyes was 93.6% versus 86.5% at day 180 and 74.6% versus 77.1% at day 360. Corneal endothelial cell loss was more common in implant-treated eyes and typically occurred after repeated implant administration. Conclusion Bimatoprost implant 15 µg met prespecified criteria for statistical and clinical noninferiority to SLT in lowering IOP, and after 1, 2, or 3 administrations, demonstrated a duration of IOP lowering similar to SLT. Bimatoprost implant 15 µg was associated with corneal adverse events in some patients, especially after repeated administrations at a fixed interval, and has been discontinued from development. A lower dose strength of implant (bimatoprost implant 10 µg, Durysta) is US Food and Drug Administration–approved for single administration.

show abstract

4‐Aza Cyclopentenone Prostaglandin Analogues: Synthesis and NF‐κB Inhibitory Activities

Doherty,

Conway,

Leveau

et al. 2024

ChemMedChem

View full text Add to dashboard Cite

Inspired by the cyclopentenone family of prostaglandins, a series of 4‐aza, cross‐conjugated cyclopentenones is described. Synthesised from N‐protected (4R)‐aza‐cyclopentenone 5, the exocyclic alkene was installed using a modified Baylis‐Hillman type aldol reaction, whereby carbon‐carbon bond formation is accompanied by dehydration. In this manner octanal and octenal, for example, can be introduced to mimic the w‐group present in the natural prostaglandins. Similarly, a focused range of alternative substituents were introduced using different aldehydes and ketones. The presence of the tert‐butyloxycarbonyl (Boc) group on the 4‐amino‐cyclopentenone substituent enabled subsequent derivatisation and various electrophiles were successfully incorporated. The ability of the family of 4‐amino functionalised cross‐conjugated cyclopentenones to block activation of nuclear factor‐kappa B (NF‐kB) was studied and compared with the natural prostanoid, D12,14‐15‐deoxy‐PGJ2 (2). Thereafter, the synthesis of a series of thiol adducts from these compounds were prepared and similarly evaluated biologically. The adducts showed comparable and, on occasion, more potent inhibition of NF‐kB than their cyclopentenone precursors and generally demonstrated diminished cytotoxicity. For example, cross‐conjugated dieneone 12 inhibited the activation of NF‐kB with an IC50 value of 6.2 mM, whereas its endocyclic N‐Boc (27) and N‐acetyl (28) cysteine adducts blocked NF‐kB activity with values of 1.0 and 8.0 mM respectively.

show abstract

Selective laser trabeculoplasty is safe and effective in patients previously treated with prostaglandin analogs: An evidence-based review

Cited by 4 publications

References 121 publications

Challenging the "Topical Medications-First” Approach to Glaucoma: A Treatment Paradigm in Evolution

Challenging the "Topical Medications-First” Approach to Glaucoma: A Treatment Paradigm in Evolution

Phase 3, Randomized Study Comparing Intracameral Bimatoprost Implant 15 μg and Selective Laser Trabeculectomy in Patients with Open-Angle Glaucoma or Ocular Hypertension

4‐Aza Cyclopentenone Prostaglandin Analogues: Synthesis and NF‐κB Inhibitory Activities

Contact Info

Product

Resources

About